2026年中期财报显示，吉林长龙药业(08049)在截至2026年6月30日止六个月内实现营收约4.35亿元，较2025年同期的4.39亿元小幅下降0.1%。公司唯一业务板块为在中国生产和分销中药及医药产品，本期营收主要来源于药物销售。
本期毛利由上一年同期的3.62亿元增长至3.65亿元，毛利率约为83.9%。期间费用方面，分销及销售成本约1.98亿元，同比下降2.58%，行政开支约0.43亿元，同比下降4.66%。经营溢利约1.52亿元，相比上一年同期的1.24亿元增长约22.6%。根据财报所示净利润约1.23亿元，同比增加约19.3%，公司方面认为这主要与生产品成本和材料费用的降低所带来的经营效率提升有关。
高管解读 董事会在公告中表示：“同时亦感谢业务伙伴，董事谨藉此机会衷心感谢管理层及员工为本集团全心全意服务及作出贡献。为未来同创佳绩，促使业务增长，董事将致力开发潜在商机。”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.